Concomitant administration of hepatitis A vaccine with measles/mumps/ rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children

Abstract

This open-label, multicenter, randomized, comparative study evaluated immunogenicity, safety and tolerability of concomitant (Group 1; n = 330) vs. non-concomitant (Group 2; n = 323) VAQTA. (25 U/0.5 mL) (hepatitis A vaccine; HA V) with ProQuad. (measles/mumps/rubella/varicella; MMRV) and Prevnar. (7-valent pneumococcal; PCV-7) in healthy, 12. 23 mo old children. Group 1 received HA V/MMRV/PCV-7 concomitantly on Day 1 and second doses of HA V/MMRV at Week 24. Group 2 received MMRV/PCV-7 on Day 1, HA V at Weeks 6 and 30 and MMRV at Week 34. Hepatitis A seropositivity rate (SPR: ≥ 10 mIU/mL; 4 weeks postdose 2), varicella zoster-virus (VZV) SPR (≥ 5 gpELISA units/mL) and geometric mean titers (GMT) to S. pneumoniae were examined. Injection-site and systemic adverse experiences (AE s) and daily temperatures were collected. Hepatitis A SPR were 100% for Group 1 and 99.4% for Group 2 after two HA V doses; risk difference = 0.7 (95% CI: -1.4, 3.8, non-inferior) regardless of initial serostatus. VZV SPR was 93.3% for Group 1 and 98.3% for Group 2; risk difference = -5.1 (95% CI: -9.3, -1.4; non-inferior). S. pneumoniae GMT fold-difference (7 serotypes) ranged from 0.9 to 1.1; non-inferior. No statistically significant differences in the incidence of individual AEs were seen when HA V was administered concomitantly vs. non-concomitantly. Three (all Group 2 post-administration of MMRV/PCV-7) of 11 serious AEs were considered possibly vaccine-related: dehydration and gastroenteritis (same subject) on Day 52; febrile seizure on Day 9. No deaths were reported. Antibody responses to each vaccine given concomitantly were non-inferior to HA V given non-concomitantly with MMRV and PCV-7. Administration of HA V with PCV-7 and MMRV had an acceptable safety profile in 12- to 23-mo-old children. © 2013 Landes Bioscience.